Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$41.09 USD
+1.58 (3.99%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $41.11 +0.02 (0.05%) 4:18 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Xenon Pharmaceuticals (XENE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$57.50 | $65.00 | $48.00 | 43.71% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Xenon Pharmaceuticals comes to $57.50. The forecasts range from a low of $48.00 to a high of $65.00. The average price target represents an increase of 43.71% from the last closing price of $40.01.
Analyst Price Targets (15)
Broker Rating
Xenon Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 15 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 83.33% and 16.67% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 15 | 15 | 15 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
3/15/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
3/15/2024 | Bloom Burton & Company | David Martin | Strong Buy | Strong Buy |
3/1/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
3/1/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
12/8/2023 | Robert W. Baird & Co. | Brian P Skorney | Not Available | Strong Buy |
11/9/2023 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
11/8/2023 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
11/8/2023 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 18 |
Average Target Price | $57.50 |
LT Growth Rate | 8.90% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -0.69 |